Sangamo Therapeutics’ efforts to secure a partnership for ST-920 (isaralgagene civoparvovec), its gene therapy for Fabry disease, should get easier now that the biotech has positive pivotal data supporting a US Food and Drug Administration filing.
Key Takeaways
- Sangamo unveiled positive data from the pivotal STAAR trial of ST-920 and plans to seek approval for the therapy in Fabry disease in 2026.
The Richmond, Calif.-based, gene therapy-focused biotech said June 24 that the pivotal Phase I/II STAAR study met the endpoint –...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?